Anzeige
Mehr »
Mittwoch, 25.06.2025 - Börsentäglich über 12.000 News
TAO +1.800?%, SBAR +85?%, CYK +280?% - jetzt startet KORA auf Unternehmensebene durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N6VA | ISIN: FR0004065605 | Ticker-Symbol: MEB
Tradegate
25.06.25 | 16:02
16,800 Euro
+1,20 % +0,200
Branche
Biotechnologie
Aktienmarkt
CAC Mid 60
1-Jahres-Chart
MEDINCELL SA Chart 1 Jahr
5-Tage-Chart
MEDINCELL SA 5-Tage-Chart
RealtimeGeldBriefZeit
16,73016,97023:00
16,74016,98022:00

Aktuelle News zur MEDINCELL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.06.Medincell Publishes its Consolidated Annual Financial Results220(April 1st, 2024 March 31st, 2025) Consolidated financial statements for the year 2024-25 (IFRS standards) Revenues: €25.4 million, multiplied by 2.8x compared to previous year ? Other...
► Artikel lesen
10.06.Medincell to Present 2024-2025 Annual Results on June 17, 2025246Regulatory News: Medincell (Paris:MEDCL) will host two live videoconferences on Tuesday, June 17, 2025, to present its financial results for the fiscal year ending March 31, 2025. The results will...
► Artikel lesen
28.05.Medincell Executives to Join Fireside Chat at Jefferies Global Healthcare Conference 2025321Regulatory News: Christophe Douat, Chief Executive Officer, and Dr. Richard Malamut, Chief Medical Officer, will present Medincell's (Paris:MEDCL) corporate overview during a fireside chat at the...
► Artikel lesen
28.05.Truist Securities Initiates Medincell's Coverage with a "Buy" Recommendation332Truist Securities, a leading U.S. investment bank with deep expertise in healthcare, has initiated coverage of Medincell The Truist Securities equity research team has issued a "Buy" rating on...
► Artikel lesen
MEDINCELL Aktie jetzt für 0€ handeln
28.05.Truist setzt Medincell-Aktie auf Kaufen mit Kursziel von 22,00€7
28.05.Truist sets Medincell stock Buy rating, EUR22 price target3
07.05.Medincell: UZEDY Continues Strong Momentum in 2025; Olanzapine LAI on Track for FDA Filing in H2 2025633Regulatory News: Medincell's partner Teva Pharmaceuticals shared today the following information: About UZEDY 1-Month and 2-Month subcutaneous risperidone for schizophrenia Commercialized...
► Artikel lesen
22.04.Medincell and iM4TB Initiate Development of a Long-Acting Injectable Version of Macozinone, a Promising Investigational Tuberculosis Treatment435iM4TB, through its participation in ERA4TB a European Union's Horizon 2020 research and innovation program is supporting initial development of a long-acting injectable (LAI) version of Macozinone...
► Artikel lesen
15.04.Medincell Increases the Amount Allocated to the Liquidity Contract with Rothschild Martin Maurel488Regulatory News: In order to accompany the increase in the volumes of shares traded daily, Medincell (Paris:MEDCL) signed on April 11, 2025 an amendment to the Liquidity Agreement entered into...
► Artikel lesen
31.03.Medincell's Partner Teva Presented Phase 3 Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with Olanzapine LAI621Regulatory News: Medincell (Paris:MEDCL): More than 92% of schizophrenia patients taking Olanzapine LAI in the Phase 3 SOLARIS survey were satisfied or very satisfied with the initiation regimen...
► Artikel lesen
06.03.Medincell verstärkt Vorstand mit Biopharma-Experte Pascal Touchon1
06.03.Medincell strengthens board with biopharma veteran Pascal Touchon1
06.03.Medincell Strengthens its Board of Directors to Support its Growth481Regulatory News: Medincell (Paris:MEDCL): Pascal Touchon joins the Board of Directors 40 years of international experience in the biopharmaceutical industry, holding operational and strategic...
► Artikel lesen
26.02.Medincell to Present at the TD Cowen 45th Annual Healthcare Conference, March 3-5, 2025, Boston, MA496Regulatory News: Medincell (Paris:MEDCL): Christophe Douat, CEO, and Richard Malamut, CMO, will present Medincell's corporate overview at the TD Cowen 45th Annual Healthcare Conference on Monday...
► Artikel lesen
25.02.Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder761UZEDY is currently approved in the US as a subcutaneous long-acting injectable (LAI) for use every one or two months for the treatment of schizophrenia in adults1 LAI treatment options...
► Artikel lesen
25.02.FDA accepts Teva, Medincell's supplemental application for UZEDY as bipolar I disorder treatment2
19.02.Medincell Announces Successful c.€43 Million Global Offering578Success of the operation with €42.9 million raised. Participation of US and European Healthcare specialist investors, as well as historical shareholders, in the transaction. Funds raised will...
► Artikel lesen
18.02.Medincell Launches a Global Offering for Approximately 10% of Its Share Capital655The Global Offering, for approximately 10% of the Company's share capital, is aimed at international institutional investors, via a Private Placement through an accelerated book-building process....
► Artikel lesen
10.02.Medincell: Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals581Medincell to receive a $5 million development milestone payment from Teva with SOLARIS study completion (last patient last visit) Richard Malamut, Chief Medical Officer at Medincell comments:...
► Artikel lesen
06.02.The EIB Reaffirms Confidence in Medincell by Permanently Waiving Two Financial Covenants in its Loan Agreement570The European Investment Bank (EIB) granted Medincell a €40 million credit facility in November 2022, fully drawn since July 2023 The EIB has decided to remove two financial covenants(1)...
► Artikel lesen
Weiter >>
48 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1